GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (STU:ASZ1) » Definitions » Cyclically Adjusted PS Ratio

Alimera Sciences (STU:ASZ1) Cyclically Adjusted PS Ratio : 0.33 (As of May. 21, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Alimera Sciences Cyclically Adjusted PS Ratio?

As of today (2024-05-21), Alimera Sciences's current share price is €2.865. Alimera Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €8.62. Alimera Sciences's Cyclically Adjusted PS Ratio for today is 0.33.

The historical rank and industry rank for Alimera Sciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:ASZ1' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.15   Med: 0.79   Max: 4.11
Current: 0.32

During the past years, Alimera Sciences's highest Cyclically Adjusted PS Ratio was 4.11. The lowest was 0.15. And the median was 0.79.

STU:ASZ1's Cyclically Adjusted PS Ratio is ranked better than
90.86% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.135 vs STU:ASZ1: 0.32

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Alimera Sciences's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.389. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €8.62 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alimera Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Alimera Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Cyclically Adjusted PS Ratio Chart

Alimera Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.97 0.51 0.58 0.29 0.45

Alimera Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.30 0.32 0.45 0.40

Competitive Comparison of Alimera Sciences's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alimera Sciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's Cyclically Adjusted PS Ratio falls into.



Alimera Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Alimera Sciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.865/8.62
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alimera Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Alimera Sciences's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.389/131.7762*131.7762
=0.389

Current CPI (Mar. 2024) = 131.7762.

Alimera Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.568 100.560 0.744
201409 0.683 100.428 0.896
201412 0.478 99.070 0.636
201503 1.231 99.621 1.628
201506 1.739 100.684 2.276
201509 2.076 100.392 2.725
201512 1.797 99.792 2.373
201603 1.736 100.470 2.277
201606 2.830 101.688 3.667
201609 1.977 101.861 2.558
201612 2.338 101.863 3.025
201703 1.431 102.862 1.833
201706 2.114 103.349 2.695
201709 1.799 104.136 2.277
201712 1.676 104.011 2.123
201803 1.676 105.290 2.098
201806 1.965 106.317 2.436
201809 2.029 106.507 2.510
201812 2.844 105.998 3.536
201903 2.419 107.251 2.972
201906 2.030 108.070 2.475
201909 2.465 108.329 2.999
201912 3.188 108.420 3.875
202003 2.641 108.902 3.196
202006 1.772 108.767 2.147
202009 2.089 109.815 2.507
202012 2.101 109.897 2.519
202103 1.637 111.754 1.930
202106 2.446 114.631 2.812
202109 1.492 115.734 1.699
202112 1.781 117.630 1.995
202203 1.545 121.301 1.678
202206 1.974 125.017 2.081
202209 1.963 125.227 2.066
202212 1.892 125.222 1.991
202303 1.799 127.348 1.862
202306 2.000 128.729 2.047
202309 0.682 129.860 0.692
202312 0.461 129.419 0.469
202403 0.389 131.776 0.389

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alimera Sciences  (STU:ASZ1) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Alimera Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alimera Sciences (STU:ASZ1) Business Description

Traded in Other Exchanges
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (STU:ASZ1) Headlines

No Headlines